Patients are requested to contact their doctors to discuss alternative
therapies
Roche, in agreement and cooperation with Health Authorities (EMEA and
Swissmedic), recalls in Europe and some other world regions all batches of
Viracept powder and tablets. The US, Canada and Japan are not affected by this
recall.
Roche has received several reports that some batches of Viracept 250 mg
tablets have a strange odour. A detailed chemical analysis of the affected
tablets showed they contain higher than normal levels of methane sulfonic acid
ethylester. In the interest of patients safety Roche has decided to recall all
batches of Viracept tablets and powder.
Patients are requested to contact their doctors to discuss alternative
therapies.
About Viracept
Viracept (nelfinavir), a protease inhibitor is supplied by Roche outside the
US and Canada. Viracept was first introduced by Roche in 1998.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading
research-focused healthcare groups in the fields of pharmaceuticals and
diagnostics. As the world’s biggest biotech company and an innovator of
products and services for the early detection, prevention, diagnosis and
treatment of diseases, the Group contributes on a broad range of fronts to
improving people’s health and quality of life. Roche is the world leader in
in-vitro diagnostics and drugs for cancer and transplantation, a market leader
in virology and active in other major therapeutic areas such as autoimmune
diseases, inflammation, metabolism and central nervous system. In 2006 sales
by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the
Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs
roughly 75,000 worldwide and has R&D agreements and strategic alliances with
numerous partners, including majority ownership interests in Genentech and
Chugai. Roche’s Diagnostics Division offers a uniquely broad product portfolio
and supplies a wide array of innovative testing products and services to
researchers, physicians, patients, hospitals and laboratories world-wide. For
further information, please visit our website at www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
